Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.69 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | SLC18A2 | Q05940 | 7/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462487 | 1.00 | HTR1A (0.69) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL28414400 | 1.00 | HTR1A (0.69) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL29462489 | 1.00 | HTR1A (0.69) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL22579521 | 0.87 | HTR1A (0.75) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL871310 | 0.87 | HTR1A (0.70) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL10018916 | 0.87 | HTR1A (0.77) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL18107625 | 0.86 | SLC18A2 (0.84) | SLC18A2 | |
| SCHEMBL873306 | 0.86 | HTR1A (0.71) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL10018923 | 0.85 | HTR1A (0.78) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL10018919 | 0.85 | HTR1A (0.78) | HTR1ATBXA2RPTGS1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306082-B2 | Esters of dihydrotetrabenazine | FORESEE PHARMACEUTICALS CO., LTD. (TW) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306082-B2 | Esters of dihydrotetrabenazine | CD4, CD2, NFATC1 | HTR1A 2856/4885TBXA2R 229/4885PTGS1 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.